Evidence map›Paper›PMID 40814048›Full record

Observational studyBMC health services research2025

Differences in the relationship between medication adherence and payer medical costs across three quality measures: results of a cohort study among medicare advantage beneficiaries.

Sujith Ramachandran, Irene Nsiah, Megha A Parikh, Patrick J Campbell, Taruja Karmakar, Heather Black, John P Bentley

Abstract readObservational Study
In one paragraph

Observational study in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sujith RamachandranUniversity of Mississippi School of Pharmacy, University, MS, USA. sramacha@olemiss.edu.
Irene NsiahUniversity of Mississippi School of Pharmacy, University, MS, USA.
Megha A ParikhPharmacy Quality Alliance, Alexandria, VA, USA.
Patrick J CampbellMerck & Co., Inc, Rahway, NJ, USA.
Taruja KarmakarMerck & Co., Inc, Rahway, NJ, USA.
Heather BlackMerck & Co., Inc, Rahway, NJ, USA.
John P BentleyUniversity of Mississippi School of Pharmacy, University, MS, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is considerable evidence that medication non-adherence is associated with higher healthcare costs. Payers and providers often target adherence quality measures for intervention, but the impact may depend on the medication. This study sought to assess differences in the relationship between medication adherence and medical (i.e., non-pharmacy) costs across three quality measures in a Medicare Advantage sample.

methodsAn observational study was conducted among cohorts of Medicare Advantage beneficiaries using the 2018-19 Optum’s de-identified Clinformatics® Data Mart Database. Cohort assignment was based on inclusion in one or all three of the Pharmacy Quality Alliance’s adherence measures for (1) renin-angiotensin-system antagonists, (2) statin, and (3) diabetes medications. Medication adherence was measured in year 1 and payer medical costs were measured in year 2. Generalized linear modeling (Gamma distribution and a log link) with interaction terms and coefficient contrasts were used to assess the relationship between adherence and subsequent payer medical costs, and to evaluate differences in this relationship across the three measures. Analyses were adjusted for sociodemographic, clinical, prescription-related, and insurance-related variables.

resultsThe single-measure cohort included 1,001,316 beneficiaries, and the three-measure cohort consisted of 284,137 beneficiaries. There were negative relationships (p < 0.0001) between adherence and payer medical costs for all medication classes. These associations were stronger for diabetes medications (0.9808; p < 0.0001), followed by renin-angiotensin-system antagonists (0.9874; p < 0.0001) and statin medications (0.9919; p < 0.0001) in the single-measure cohort. The findings were similar among beneficiaries using all three medication classes.

conclusionsBetter adherence was associated with lower payer medical costs across several therapeutic areas, providing additional evidence of the importance of adherence in managing health care costs. The relationship between adherence and subsequent year medical costs appears stronger for diabetes medications relative to renin-angiotensin-system antagonists or statins. Further research may explore interventions to increase adherence to diabetes medications to improve diabetes management.

Indexed as

Drug MonitoringHealth Care CostsHealth ExpendituresMedicare Part CQuality Indicators, Health CareAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsCohort StudiesDiabetes MellitusFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsMaleUnited StatesAngiotensin-Converting Enzyme InhibitorsHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsMedical costsMedicare advantageMedication adherencePDC

Identifiers

PMID40814048
PMCPMC12351825

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.